The Vision of Banner Alzheimer’s Institute
Banner Alzheimer’s Institute:
Where hope begins, and Alzheimer’s disease ends.
At Banner Alzheimer's Institute (BAI), our vision can be summed up in three strategically focused and ambitious—but highly achievable—goals:
- Ending Alzheimer's Disease without losing another generation
- Establishing a new standard of care for patients and families
- Forging a model of collaboration in biomedical research
Ending Alzheimer's Disease without losing another generation
The worldwide cost of dementia will exceed 1 percent of global GDP in 2010, at $604 billion. If dementia care were a country, it would be the world's 18th largest economy. If it were a company, it would be the world's largest by annual revenue exceeding Wal-Mart ($414 billion) and Exxon Mobil ($311 billion). (Alzheimer’s Disease International) Estimates are made that 35.6 million people live with Alzheimer’s disease and other dementias worldwide today, increasing to 65.7 million by 2030 and 115.4 million by 2050. For all these reasons, there is an urgent need to find demonstrably effective treatments to stop and end Alzheimer's Disease, starting now. Learn more
Establishing a new standard of care for patients and families
At BAI, our standard of care is unique: access to tomorrow’s treatments today. As a premier destination center for patients and families within Arizona and internationally, our multi-disciplinary approach allows a team of specialists (psychiatrist, neuropsychiatrists, neurologists, physician assistances, nurses and social workers to help patients and caregivers prepare for both the future and daily experiences. Our innovative family and community services programs range from art therapy and yoga to support groups and planning ahead services. Learn more
Forging a model of collaboration in biomedical research
Eric Reiman, MD, executive director of BAI, also leads the Arizona Alzheimer's Consortium, which is a model of multi-institutional, multi-disciplinary collaboration in biomedical research. The Consortium is the nation's leading statewide collaboration in Alzheimer's Disease research, and one of the leading research programs in the world. This collaborative model capitalizes on complimentary resources in brain imaging, mathematical and computational analysis, genomics, cognitive and behavioral neurosciences, experimental therapeutic programs, and neuropathology research, to address specific questions in a more fundamental way. Learn more
